Leptomeningeal dissemination in glioblastoma; an inspection of risk factors, treatment, and outcomes at a single institution
- 511 Downloads
- 10 Citations
Abstract
There are few studies reporting the incidence of leptomeningeal dissemination (LMD) in patients with glioblastoma; only small case series have been published. Consequently, there are no established standards of care for these patients. Therefore, we undertook this retrospective review to evaluate a large series of patients with glioblastoma treated at MD Anderson Cancer Center to estimate the incidence of LMD and assess the impact of a variety of treatment modalities. Analysis was performed on 595 patients with glioblastoma treated on clinical trials from 2006 to 2012. The diagnosis of LMD was made by imaging or positive cerebrospinal fluid cytology in 24 patients. An additional 12 patients with known LMD diagnosed during this same period were included to evaluate the impact of treatment on outcome for a total of 36 patients. LMD developed in 4.0 % (24/595 patients) of the clinical trial cohort. Median survival from glioblastoma diagnosis was 16.0 months. Estimated median time of glioblastoma diagnosis to LMD was 11.9 months. Median overall survival from the time of LMD diagnosis was 3.5 months. Patients treated for LMD with chemotherapy/targeted therapy and radiation had a significantly prolonged survival (7.7 months) compared to chemotherapy/targeted therapy alone, radiation alone or palliative care. LMD remains an uncommon event in patients with glioblastoma. Patients treated aggressively with chemotherapy/targeted therapy and radiation had the longest median survival following diagnosis of LMD. However, patients receiving chemotherapy/targeted therapy and radiation were younger and this may have influenced survival. Given the overall poor outcomes, improved therapeutic approaches are needed for glioblastoma patients with LMD.
Keywords
Glioblastoma Leptomeningeal dissemination Leptomeningeal gliomatosisNotes
Conflict of interest
No conflict of interests to report.
References
- 1.Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996PubMedCrossRefGoogle Scholar
- 2.Yung WA, Horten BC, Shapiro WR (1980) Meningeal gliomatosis: a review of 12 cases. Ann Neurol 8(6):605–608PubMedCrossRefGoogle Scholar
- 3.Vertosick FT Jr, Selker RG (1990) Brain stem and spinal metastases of supratentorial glioblastoma multiforme: a clinical series. Neurosurgery 27(4):516–521 discussion 521–2PubMedCrossRefGoogle Scholar
- 4.Arita N, Taneda M, Hayakawa T (1994) Leptomeningeal dissemination of malignant gliomas. Incidence, diagnosis and outcome. Acta Neurochir (Wien) 126(2–4):84–92CrossRefGoogle Scholar
- 5.Engelhard HH, Corsten LA (2005) Leptomeningeal metastasis of primary central nervous system (CNS) neoplasms. Cancer Treat Res 125:71–85PubMedCrossRefGoogle Scholar
- 6.Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466. doi: 10.1016/S1470-2045(09)70025-7 PubMedCrossRefGoogle Scholar
- 7.de Groot JF, Fuller G, Kumar AJ et al (2010) Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro-Oncology. 12(3):233–242PubMedCentralPubMedCrossRefGoogle Scholar
- 8.Lu KV, Chang JP, Parachoniak CA et al (2012) VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 22(1):21–35. doi: 10.1016/j.ccr.2012.05.037 PubMedCentralPubMedCrossRefGoogle Scholar
- 9.Clarke JL (2012) Leptomeningeal metastasis from systemic cancer. Continuum (Minneap Minn). 18(2):328–342. doi: 10.1212/01 PubMedGoogle Scholar
- 10.Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481CrossRefGoogle Scholar
- 11.Korshunov A, Sycheva R, Golanov A, Pronin I (2007) Gains at the 1p36 chromosomal region are associated with symptomatic leptomeningeal dissemination of supratentorial glioblastomas. Am J Clin Pathol 127(4):585–590PubMedCrossRefGoogle Scholar
- 12.Kato H, Fujimura M, Kumabe T, Ishioka C, Kanamaru R, Yoshimoto T (2004) PTEN gene mutation and high MIB-1 labeling index may contribute to dissemination in patients with glioblastoma. J Clin Neurosci 11(1):37–41PubMedCrossRefGoogle Scholar
- 13.Herrlinger U, Wiendl H, Renninger M, Förschler H, Dichgans J, Weller M (2004) Vascular endothelial growth factor (VEGF) in leptomeningeal metastasis: diagnostic and prognostic value. Br J Cancer 91:219–224. doi: 10.1038/sj.bjc.6601953www.bjcancer.com PubMedCentralPubMedGoogle Scholar
- 14.Chamberlain MC (2003) Combined-modality treatment of leptomeningeal gliomatosis. Neurosurgery 52(2):324–329PubMedCrossRefGoogle Scholar
- 15.Le Rhun E, Taillibert S, Chamberlain MC (2013) Carcinomatous meningitis: leptomeningeal metastases in solid tumors. Surg Neurol Int 2(4(Suppl 4)):S265–S288. doi: 10.4103/2152-7806.111304 Google Scholar
- 16.Chamberlain MC (2013) Prognostic utility of neuraxis imaging in leptomeningeal metastasis: a retrospective case series. Eur Assoc Neuro Oncol 3(1):6–10Google Scholar
- 17.Chamberlain MC, Soffietti R, Raizer J et al (2014) Leptomeningeal metastasis: a response assessment in neuro-oncology critical review of endpoints and response criteria of published randomized clinical trials. Neuro Oncol. doi: 10.1093/neuonc/nou089 Google Scholar
- 18.Chamberlain MC (2013) Comprehensive neuraxis imaging in leptomeningeal metastasis: a retrospective case series. CNS Oncol 2(2):121–128. doi: 10.2217/cns.12.45 PubMedCrossRefGoogle Scholar